Ascend Wellness Reports Q1 2026: Revenue & EBITDA Decline, Net Loss Improves, Q2 Outlook Positive

summarizeSummary

Ascend Wellness Holdings reported a sequential decline in Q1 2026 revenue and Adjusted EBITDA, but an improved net loss and gross margin, alongside a positive Q2 outlook and strategic benefits from cannabis rescheduling.

check_boxKey Events

• Q1 2026 Financial Performance

  Net revenue declined to $116.9 million (down 3.0% sequentially, 8.6% YoY), and Adjusted EBITDA fell to $26.3 million (down 12.9% sequentially, 2.5% YoY). Net loss improved sequentially to $29.5 million from $48.7 million in Q4 2025, and Adjusted Gross Profit Margin increased to 46.1%.

• Cash Position and Outflow

  The company reported $60.9 million in cash and cash equivalents. Net cash outflow from operating activities was $19.4 million, including a $19.1 million bi-annual interest payment and a $17.0 million arbitration settlement payment.

• Operational Expansion and Brand Strength

  Ascend added five new dispensaries year-to-date and plans for 10 more, aiming for 60 stores by year-end. Its Ozone and High Wired brands showed strong performance, with High Wired ranking #1 in the infused flower category in key markets.

• Q2 2026 Outlook

  The company anticipates a 2-3% increase in revenue and expects Adjusted EBITDA Margin to remain in the low-20% range, driven by new store openings and favorable seasonality.

auto_awesomeAnalysis

Ascend Wellness Holdings reported mixed Q1 2026 financial results, with both net revenue and Adjusted EBITDA declining sequentially and year-over-year. However, the company saw an improvement in its net loss compared to the previous quarter and an increase in Adjusted Gross Profit Margin. A significant cash outflow from operations was noted, partly due to a large interest payment and an arbitration settlement. Operationally, the company is expanding its retail footprint and seeing strong brand performance. The positive outlook for Q2 2026 revenue growth and stable EBITDA margins, coupled with the potential benefits from the rescheduling of medical cannabis, provides some optimism amidst ongoing financial challenges.